First Trust Nasdaq Pharmaceuticals ETF (FTXH)
|Ex-Dividend Date||Sep 23, 2021|
|Day's Range||25.81 - 26.10|
|Inception Date||Sep 20, 2016|
The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of the Nasdaq US Smart Pharmaceuticals Index. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depository receipts that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and weighted based upon their cumulative score on three investing factors: volatility, value and growth. It is non-diversified.
Top 10 Holdings59.55% of assets
|Prestige Consumer Healthcare||PBH||8.38%|
|Johnson & Johnson||JNJ||7.63%|
|Sep 23, 2021||$0.0393||Sep 30, 2021|
|Jun 24, 2021||$0.0533||Jun 30, 2021|
|Mar 25, 2021||$0.0771||Mar 31, 2021|
|Dec 24, 2020||$0.0644||Dec 31, 2020|
|Sep 24, 2020||$0.0428||Sep 30, 2020|
|Jun 25, 2020||$0.0463||Jun 30, 2020|
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development as the outbreak worsens.
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development.
The First Trust Nasdaq Pharmaceuticals ETF (FTXH) has hit a new 52-week high. Are more gains in store?
There are at least a hundred candidates in the COVID-19 vaccine race globally. However, few companies like Moderna, Pfizer and AstraZeneca are showing considerable hope.
ETF Spotlight: Pharmaceuticals driven higher by Pfizer
CNBC'S Morgan Brennan takes a look at pharmaceutical as Pfizer's positive vaccine news has led the sector higher.
Robust results led to solid trading in pharma ETFs in a month.
Despite robust results, pharma ETFs have been trending downward in a month.